Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.

NEXGEL, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MANAGEMENT WILL HOST A CONFERENCE CALL AT 4:30 P.M. ET ON THE SAME DAY LANGHORNE, PA.

NEXGEL TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 12TH

LANGHORNE, PA., AUG. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, INC. (NEXGEL OR THE COMPANY) (NASDAQ: NXGL), A LEADING PROVIDER OF MEDICAL AND OVER-THE-COUNTER (OTC) PRODUCTS INCLUDING ULTRA-GENTLE, HIGH-WATER-CONTENT HYDROGELS FOR HEALTHCARE AND CONSUMER APPLICATIONS, TODAY ANNOUNCED THE APPOINTMENT OF STEVE CIARDIELLO, CPA, TO ITS BOARD OF DIRECTORS.

NEXGEL APPOINTS CHIEF ACCOUNTING OFFICER OF SHUTTERSTOCK, STEVE CIARDIELLO, CPA, TO ITS BOARD OF DIRECTORS

LANGHORNE, PA., AUG. 01, 2025 (GLOBE NEWSWIRE) -- NEXGEL, INC. (NEXGEL OR THE COMPANY) (NASDAQ: NXGL), A LEADING PROVIDER OF MEDICAL AND OVER-THE-COUNTER (OTC) PRODUCTS INCLUDING ULTRA-GENTLE, HIGH-WATER-CONTENT HYDROGELS FOR HEALTHCARE AND CONSUMER APPLICATIONS, TODAY ANNOUNCED IT HAS ENTERED INTO DEFINITIVE AGREEMENTS FOR THE ISSUANCE AND SALE OF AN AGGREGATE OF 413,044 SHARES OF ITS COMMON STOCK (THE SHARES) AT $2.30 A SHARE. IN A CONCURRENT PRIVATE PLACEMENT, NEXGEL ALSO AGREED TO ISSUE TO THE INVESTORS IN THE REGISTERED DIRECT OFFERING UNREGISTERED WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 206,522 SHARES OF COMMON STOCK (THE UNREGISTERED WARRANTS). THE UNREGISTERED WARRANTS WILL HAVE AN EXERCISE PRICE OF $4.25 PER SHARE AND ARE EXERCISABLE IMMEDIATELY UPON ISSUANCE WITH A TERM OF FIVE YEARS FROM THE DATE OF ISSUANCE.

NEXGEL ANNOUNCES $950,000 REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT

LANGHORNE, PA., JULY 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, INC. (NEXGEL OR THE COMPANY) (NASDAQ: NXGL), A LEADING PROVIDER OF ULTRA-GENTLE, HIGH-WATER-CONTENT HYDROGEL PRODUCTS FOR HEALTHCARE AND CONSUMER APPLICATIONS, TODAY ANNOUNCED EXPANDING ITS PARTNERSHIP WITH STADA ARZNEIMITTEL AG (STADA), A EUROPEAN LEADER IN CONSUMER HEALTH. THE EXPANSION INCLUDES THE PLANNED LAUNCH OF DIGESTIVE ENZYME FORMULAS AND SOLUTIONS TARGETING SCARS AND STRETCH MARKS.

NEXGEL AND STADA AG ANNOUNCE EXPANSION OF PARTNERSHIP FOR NORTH AMERICA

NEXGEL TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MAY 13TH

FOURTH QUARTER 2024 REVENUE TOTALED $3.04 MILLION, AN INCREASE OF 181%, AS COMPARED TO $1.08 MILLION FOR THE SAME PERIOD THE PRIOR YEAR

NEXGEL REPORTS RECORD FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS

NEXGEL TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ON MARCH 24TH

LANGHORNE, PA., FEB. 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, INC. (NEXGEL OR THE COMPANY) (NASDAQ: NXGL), A LEADING PROVIDER OF MEDICAL AND OVER-THE-COUNTER (OTC) PRODUCTS INCLUDING ULTRA-GENTLE, HIGH-WATER-CONTENT HYDROGELS FOR HEALTHCARE AND CONSUMER APPLICATIONS, TODAY ANNOUNCED THAT ADAM LEVY, CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE WEBULL CONSUMER VIRTUAL WEBINAR ON FEBRUARY 18, 2025.

NEXGEL TO PARTICIPATE IN WEBULL CONSUMER VIRTUAL WEBINAR ON FEBRUARY 18, 2025

LANGHORNE, PA., JAN. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, INC. (NEXGEL OR THE COMPANY) (NASDAQ: NXGL), A LEADING PROVIDER OF MEDICAL AND OVER-THE-COUNTER (OTC) PRODUCTS INCLUDING ULTRA-GENTLE, HIGH-WATER-CONTENT HYDROGELS FOR HEALTHCARE AND CONSUMER APPLICATIONS, TODAY ANNOUNCED THE APPOINTMENT OF JOSEPH F. MCGUIRE AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2025. ADAM E. DRAPCZUK III, CURRENT CHIEF FINANCIAL OFFICER, WILL REMAIN WITH THE COMPANY AS A CONSULTANT.

NEXGEL APPOINTS JOSEPH F. MCGUIRE AS CHIEF FINANCIAL OFFICER

QUARTERLY REVENUE GROWTH DRIVEN BY A SEQUENTIAL INCREASE OF 99% IN BRANDED CONSUMER PRODUCTS AND 103% IN CONTRACT MANUFACTURING

NEXGEL, Inc.

NXGL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NEXGEL, Inc.

NXGL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NXGL